Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGN-CD70A in CD70-positive malignancies
NCT02216890Phase 1Completed
- Sponsor
- Seagen Inc.
- Start
- Aug 2014
- Primary completion
- Feb 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SGN-CD70A in renal cell carcinoma (RCC), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and 1 more, sponsored by Seagen Inc. Primary endpoints: Incidence of adverse events and Incidence of laboratory abnormalities. Started Aug 2014; status: completed.
02
Drugs
SGN-CD70A
03
Conditions
renal cell carcinoma (RCC)mantle cell lymphoma (MCL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02216890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02216890.